GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (OTCPK:RLFTF) » Definitions » PB Ratio

RLFTF (Relief Therapeutics Holding) PB Ratio : 0.98 (As of Dec. 13, 2024)


View and export this data going back to 1990. Start your Free Trial

What is Relief Therapeutics Holding PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-13), Relief Therapeutics Holding's share price is $4.29. Relief Therapeutics Holding's Book Value per Share for the quarter that ended in Jun. 2024 was $4.40. Hence, Relief Therapeutics Holding's PB Ratio of today is 0.98.

The historical rank and industry rank for Relief Therapeutics Holding's PB Ratio or its related term are showing as below:

RLFTF' s PB Ratio Range Over the Past 10 Years
Min: 0.1   Med: 0.86   Max: 56.93
Current: 0.93

During the past 13 years, Relief Therapeutics Holding's highest PB Ratio was 56.93. The lowest was 0.10. And the median was 0.86.

RLFTF's PB Ratio is ranked better than
82.96% of 1279 companies
in the Biotechnology industry
Industry Median: 2.48 vs RLFTF: 0.93

During the past 12 months, Relief Therapeutics Holding's average Book Value Per Share Growth Rate was -49.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -20.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 17.40% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Relief Therapeutics Holding was 69.60% per year. The lowest was -60.00% per year. And the median was -3.75% per year.

Back to Basics: PB Ratio


Relief Therapeutics Holding PB Ratio Historical Data

The historical data trend for Relief Therapeutics Holding's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding PB Ratio Chart

Relief Therapeutics Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 13.34 1.35 0.83 0.46

Relief Therapeutics Holding Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.81 0.83 0.36 0.46 0.30

Competitive Comparison of Relief Therapeutics Holding's PB Ratio

For the Biotechnology subindustry, Relief Therapeutics Holding's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relief Therapeutics Holding's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's PB Ratio distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's PB Ratio falls into.



Relief Therapeutics Holding PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Relief Therapeutics Holding's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2024)
=4.29/4.395
=0.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Relief Therapeutics Holding  (OTCPK:RLFTF) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Relief Therapeutics Holding PB Ratio Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Relief Therapeutics Holding Business Description

Traded in Other Exchanges
Address
Avenue de Secheron 15, Geneva, CHE, 1202
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development such as RLF-TD011, and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast among others. Geographically the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.